Communiqués Werewolf Therapeutics, Inc.

Actions

HOWL

US95075A1079

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 11/09/2026			Varia. 5j.	Varia. 1 janv.
0,9820 ^USD	-0,66%		+1,62%	+55,01%

21/08	Werewolf Therapeutics fusionne avec Ambros Therapeutics dans le cadre d'une transaction entièrement en actions	MT
21/08	Les plus fortes hausses en pré-séance	MT

Communiqués

24/08	Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement	AQ
21/08	Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement	AQ
31/07	Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates	AQ
08/05	Werewolf Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates	AQ
30/03	Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates	AQ
27/03	Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates	AQ
24/02	Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives	AQ
18/12	Werewolf Therapeutics Announces Pipeline and Business Updates	AQ
07/11	Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting	AQ
04/11	Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update	AQ
08/10/25	Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer	AQ
06/10/25	Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's 40th Annual Meeting	AQ
03/10/25	Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting	AQ
02/09/25	Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference	AQ
14/08/25	Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update	AQ
09/07/25	Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit	AQ
12/06/25	Werewolf Therapeutics to Participate in the BIO International Convention	AQ
29/05/25	Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference	GL
20/05/25	HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124	AQ
13/05/25	Werewolf Therapeutics to Participate in Hanson Wade’s 6th Annual Cytokine-Based Drug Development Summit	AQ
08/05/25	Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update	AQ
05/05/25	Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting	AQ
05/05/25	Werewolf Therapeutics to Participate in Upcoming Investor Conferences	AQ
17/04/25	Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer	AQ